Cancer Drugs Under Development

Publication
Article
OncologyONCOLOGY Vol 9 No 2
Volume 9
Issue 2

According to the Pharmaceutical Research and Manufacturers of America, as of 1993, 124 cancer drugs were in some stage of development at 49 pharmaceutical companies and the National Cancer Institute. The report was based on an NCI survey.

According to the Pharmaceutical Research and Manufacturers ofAmerica, as of 1993, 124 cancer drugs were in some stage of developmentat 49 pharmaceutical companies and the National Cancer Institute.The report was based on an NCI survey. At least 16 of the upcomingcancer drugs are genetically engineered. Since many of these drugsare targeted to more than one type of cancer, 223 research projectsare ongoing.

Articles in this issue
New Noninvasive Test May Improve Breast Cancer Diagnosis and Reduce Unnecessary Biopsies
Cancer Drugs Under Development
Early Results of RTOG Small-Cell Lung Cancer Trial
The Economics of Oncology: Health System Reform and Clinical Research
An Update on the Pros and Cons of Preventive Mastectomy
The Effect of Tamoxifen on the Endometrium
Commentary (Look): The Effect of Tamoxifen on the Endometrium
Commentary (Kimmick/Muss): The Effect of Tamoxifen on the Endometrium
Management of Papillary Thyroid Cancer
Commentary (Cady): Management of Papillary Thyroid Cancer
The Management of Early Ovarian Cancer
Commentary (Markman): The Management of Early Ovarian Cancer
Commentary (Thigpen): The Management of Early Ovarian Cancer
Recent Videos
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Related Content
The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.

FDA Approves FoundationOne CDx Diagnostic for Tovorafenib in Brain Tumors

Roman Fabbricatore
January 20th 2025
Article

The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Psilocybin May Help Address Cancer-Related Psychological Concerns

Michael P. Bogenschutz, MD
January 20th 2025
Podcast

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Integrating Psilocybin-Assisted Psychotherapy in Comprehensive Cancer Care

Michael P. Bogenschutz, MD
January 20th 2025
Article

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

Tim Cortese
January 18th 2025
Article

The DCISionRT test has shown to be a significant factor in a clinician’s recommendation on whether a patient with DCIS should receive radiotherapy.

UGN-102 May Be Nonsurgical Alternative to TURBT in Low-grade Bladder Cancer

UGN-102 May Be Nonsurgical Alternative to TURBT in Low-grade Bladder Cancer

Tim Cortese
January 18th 2025
Article

UGN-102 elicited complete responses in 79.6% of patients with non–muscle-invasive bladder cancer at 3 months in the ENVISION trial.